Susan Hasty, Publisher
Table of Contents . . . August 23rd, 1999Non-Subscriber - Summaries Only
Therapy (HBV) - L528M Mutation is Risk Factor for Nucleoside Breakthrough
Coinfection (HCV/HGV) - Dual HCV/HGV Infection Low in Asian Study
Coinfection (HCV/TTV) - IFN Does Not Influence TTV Levels in HCV+
Controversies (Pediatrics) - Infant HBV Vaccination Debated in Congressional Hearing
Non-Hodgkin's Lymphoma (Etiology) - Link Between HCV and NHL Examined
Interferon Therapy - Immune Response Not Related to IFN Efficacy
Hepatitis B Vaccine - Novel HBV Vaccine Shows Efficacy
Risk Factors - HCV Genotype Doesn't Impact Outcome in Renal Patients
Pediatrics (HBV Therapy) - Guidelines for HBV Treatment of Children Debated
Therapy (HBV) - Interferon Retreatment Useful in HBeAg+ Disease
Industry News (Blood Transfusion) - Agreement Expands Access to PLAS+SD
Industry News (Blood Transfusion) - Vitex Files To Commence Trials of New "Universal" Plasma
Quality of Life (HCV) - Benefits of Combination Therapy Are Not Just Long-Term
Therapy (HCV) - ALT Variables Linked to IFN Nonresponse
Epidemiology (HCV) - "Decline in Prevalence and Incidence of Hepatitis C in Hemodialysis Patients (HD)."
Autoimmune Hepatitis - "Genetic Heterogeneity in Susceptibility to Autoimmune Hepatitis Types 1 and 2."
Neurology (HCV) - "Neurological Manifestations of Chronic Hepatitis C."
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.